İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2022 · article

P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS

Dergi Ovid Technologies (Wolters Kluwer Health) ISSN kaydı başka bir dergiye işaret ediyor; ad YÖKSİS kaydından.
ISSN2572-9241
YÖKSİS OpenAlex Açık erişim · gold
Yıl2022
Atıf0OpenAlex
Yüzdelik%6,8
FWCI0,01,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıOvid Technologies (Wolters Kluwer Health)
  • Katalog eşleşmesi (ISSN)HemaSphere
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Introduction: Patients with multiple myeloma (MM) have an inherently compromised humoral and cellular immunity predisposing to Covid-19 infection. Factors associated with increased risk of adverse COVID-19 outcome is unclear. The aim of our retrospective analysis was to evaluate COVID-19 infection outcome among our myeloma patients and to define the possible prognostic parameters. Patients And Methods: Between March 2020- February 2022, 10 myeloma patients were diagnosed with COVID infection confirmed by PCR test and computer tomography (CT). The severity of SARS-CoV-2 infection was classified according to WHO definition as: mild: symptomatic without pneumonia or hypoxia; moderate: with or without signs of pneumonia with SpO2 >90% on room air; severe disease: with symptoms of pneumonia and respiratory rate> 30/min, severe respiratory distress or SpO2 <90% on room air. Critical disease: with acute respiratory distress syndrome (ARDS), sepsis and septic shock. In addition, CALL (comorbidity-age-lymphocyte count-lactate dehydrogenase) score was used. All patients were given supportive care including heparin and 0.4 gr/kg/day intravenous immunoglobulin for those presenting with immunoparesis regardless of IgG treshold of 4.0 gr/L. Convalescent or monoclonal plasma was not used. All anti-myeloma treatments were discontinued until full recovery. Results: Baseline characteristics of our patients are summarized in Table 1. The median age at onset of COVID-19 was 62 years. Three patients were therapy naïve, two newly diagnosed MM and one with smoldering MM. At the time point of COVID-19 diagnosis, eight patients were being followed without treatment. Twenty patients were followed out-patient without any treatment and with full recovery. Eighteen (16%) patients were admitted to ICU and 13 (12%) required invasive mechanic ventilation. Two patients received hydroxychloroquine, 68 received favipiravir, one patient received anakinra and two patients received tocilizumab. Full recovery from COVID-19 infection with regression of clinic symptoms and achievement of PCR negativity of COVID-19 was observed in 93 (84.5%) patients and 17 (15.5%) patients died due to severe COVID-19 pneumonia with respiratory and multi-organ failure. No death due to thromboembolic event was observed. As expected, high CALL risk score (HR:0.17 (95% CI: 0.06-0.48) and higher COVID severity grade (HR:0.26 (95% CI: 0.07-0.97) were detrimental. Age did not have an impact. However response

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

0atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

13
  1. GÜLDANE CENGİZ SEVAL 1
  2. EKİN KIRCALI 2
  3. DERYA KOYUN 3
  4. BÜLENT KARAKAYA 4
  5. HÜLYA YILMAZ 5
  6. GÜL YAVUZ ERMİŞ 6
  7. HAKAN AKBULUT ANKARA ÜNİVERSİTESİ 7
  8. SELAMİ KOÇAK TOPRAK 8
  9. PERVİN TOPÇUOĞLU ANKARA ÜNİVERSİTESİ 9
  10. ÖNDER ARSLAN 10
  11. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 11
  12. OSMAN İLHAN LOKMAN HEKİM ÜNİVERSİTESİ 12
  13. MERAL BEKSAÇ 13